Marker Therapeutics
Develops non-genetically modified multi-antigen T-cell therapies for lymphoma, pancreatic cancer, AML, and MDS.
Something off on this page? Send us feedback.
Profile
Develops non-genetically modified, multi-antigen T-cell therapies, led by MT-601 for lymphoma and pancreatic cancer and MT-401-OTS for AML and MDS. Operates without approved products or product sales, relying on Baylor-licensed technology, external manufacturing, grants, and financing.
Develops non-genetically modified, multi-antigen recognizing T-cell therapies for blood cancers and pancreatic cancer. Its autologous MT-601 program is being studied in lymphoma after anti-CD19 CAR-T treatment or when CAR-T is unsuitable, with a separate planned pancreatic-cancer study; its donor-derived MT-401-OTS program is in early development for AML and MDS.
Operates as a lean, single research-and-development segment with no approved products or product-sale or licensing revenue. The platform's intellectual property is exclusively licensed from Baylor College of Medicine, which supplies current clinical material, while Cellipont Bioservices handles MT-601 technology transfer and manufacturing scale-up. Future commercialization or licensing would carry Baylor royalties; clinical advancement depends on trials, regulatory approvals, grant support, financing, and external manufacturing.
Company facts
Key statistics
Year to date −12.3% · Average volume (30d) 65.5K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | −$0.25 | −$0.09 | +64.0% | $694.0K | — | — | +2.70% |
| May 15, 2026Q1 FY26 | −$0.18 | −$0.16 | +11.1% | $783.9K | — | — | −2.11% |
| Mar 18, 2026Q4 FY25 | −$0.21 | −$0.04 | +81.0% | $682.1K | $1.1M | +61.3% | −1.49% |
| Nov 13, 2025Q3 FY25 | −$0.36 | −$0.12 | +66.7% | $723.0K | $1.2M | +70.5% | +3.48% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $349.1K | $861.2K | $1.2M | $0 | $0 | $0 | |
| Gross profit | −$2.8M | −$3.3M | −$1.1M | $0 | −$2.8M | $0 | |
| Operating income | −$4.6M | −$4.3M | −$2.1M | −$1.9M | −$4.1M | −$2.6M | |
| Net income | −$4.4M | −$4.0M | −$2.0M | −$1.7M | −$3.2M | −$1.8M | |
| Diluted EPS | −$0.40 | −$0.29 | −$0.12 | −$0.10 | −$0.16 | −$0.10 | |
| Gross margin | -798.1% | -385.0% | -90.3% | — | — | — | |
| Operating margin | -1,320.1% | -494.8% | -173.3% | — | — | — |
Fiscal years (4-quarter sums)FY21 $1.2M · FY22 $3.5M · FY23 $3.3M · FY24 $6.6M · FY25 $2.4M
Revenue by product · Q4 FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $11.3M · Total debt $0 · Total assets $14.6M · Shareholders' equity $12.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 16.67M · Float 13.50M · 81.0% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 1.67M | 9.90% | 13D | Nov 17, 2025 |
| Nea Management Company, LLC | 1.63M | 9.75% | 13F | Aug 14, 2026 |
| Alyeska Investment Group, L.P. | 1.28M | 9.90% | 13G | Nov 14, 2025 |
| Blue Owl Capital Holdings LP | 554.3K | 3.32% | 13F | Aug 11, 2026 |
| Vanguard Capital Management LLC | 426.2K | 2.56% | 13F | Aug 13, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Gilead Sciences
Yescarta sets the CD19 CAR-T standard in large B-cell lymphoma.
- Bristol-Myers Squibb
Breyanzi is a scaled CD19 CAR-T option in large B-cell lymphoma.
- Genmab (ADR)
Epkinly offers an off-the-shelf CD20xCD3 option in relapsed lymphoma.
- Allogene Therapeutics
Cema-cel pursues off-the-shelf CAR-T in large B-cell lymphoma.
- Caribou Biosciences
Vispa-cel advances genome-edited allogeneic CAR-T for B-cell lymphoma.
- Novartis (ADR)
Kymriah is an established CD19 CAR-T therapy for B-cell lymphoma.
- CRISPR Therapeutics
Zugo-cel is an investigational allogeneic CD19 CAR-T in blood cancers.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Marker Therapeutics | $1.37 | +1.75% | $22.8M | — | — | 18.5 | −51.2% |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Genmab (ADR) | $33.25 | +0.09% | $20.40B | 26.2 | 25.9 | 2.1 | +24.9% |
| Allogene Therapeutics | $2.01 | −0.09% | $697.2M | — | — | 150.3 | — |
| Caribou Biosciences | $1.65 | +2.17% | $160.7M | — | — | 16.0 | −43.8% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Median | 23.2 | 16.2 | 5.9 | +8.0% |